Canagliflozin Improves Erythropoiesis in Diabetes Patients with Anemia of Chronic Kidney Disease

Diabetes Technology and Therapeutics

Volumn 21, Issue 12, 2019, Pages 713-720

  Maruyama, Takashi ^a   Takashima, Hiroyuki ^a   Oguma, Hidetaka ^a   Nakamura, Yoshihiro ^a   Ohno, Michiko ^a   Utsunomiya, Kei ^a   Furukawa, Tetsuya ^a   Tei, Ritsukou ^a   Abe, Masanori ^a  

^a NIHON UNIVERSITY   (Japan)

Author keywords

Canagliflozin; Chronic kidney disease; Erythropoiesis; Erythropoietin; Renal anemia; Type 2 diabetes

Indexed keywords

CANAGLIFLOZIN; HEMOGLOBIN; TRANSFERRIN; GLYCOSYLATED HEMOGLOBIN;

AGED; ANEMIA; ARTICLE; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; DIABETIC PATIENT; DRUG EFFECT; ERYTHROCYTE COUNT; ERYTHROPOIESIS; FEMALE; FERRITIN BLOOD LEVEL; GLYCEMIC CONTROL; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HUMAN; KIDNEY FUNCTION; MALE; METABOLIC PARAMETERS; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETICULOCYTE COUNT; SINGLE BLIND PROCEDURE; BLOOD; COMPLICATION; MIDDLE AGED; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANEMIA; CANAGLIFLOZIN; DIABETES MELLITUS, TYPE 2; ERYTHROCYTE COUNT; ERYTHROPOIESIS; FEMALE; GLYCATED HEMOGLOBIN A; HEMATOCRIT; HUMANS; MALE; MIDDLE AGED; RENAL INSUFFICIENCY, CHRONIC; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS; TREATMENT OUTCOME;

EID: 85075932197     PISSN: 15209156     EISSN: 15578593     Source Type: Journal    
DOI: 10.1089/dia.2019.0212     Document Type: Article

References (33)

1. Polidori D, Mari A, Ferrannini E: Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves model-based indices of beta cell function in patients with type 2 diabetes. Diabetologia 2014;57:891-901.
2. Inagaki N, Kondo K, Yoshinari T, et al.: Efficacy and safety of canagliflozin alone or as add-on to other oral antihyperglycemic drugs in Japanese patients with type 2 diabetes: a 52-week open-label study. J Diabetes Investig 2015;6:210-218.
3. Komala MG, Panchapakesan U, Pollock C, et al.: Sodium glucose cotransporter 2 and the diabetic kidney. Curr Opin Nephrol Hypertens 2013;22:113-119.
4. Cherney DZ, Perkins BA, Soleymanlou N, et al.: Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 2014;129:587-597.
5. Novikov A, Vallon V: Sodium glucose cotransporter 2 inhibition in the diabetic kidney: an update. Curr Opin Nephrol Hypertens 2016;25:50-58.
6. Panchapakesan U, Pegg K, Gross S, et al.: Effects of SGLT2 inhibition in human kidney proximal tubular cells-renoprotection in diabetic nephropathy? PLoS One 2013;8:e54442.
7. Zinman B, Wanner C, Lachin JM, et al.: Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117-2128.
8. Haase VH: Hypoxia-inducible factors in the kidney. Am J Physiol Renal Physiol 2006; 291:F271-F281.
9. Lambers Heerspink HJ, de Zeeuw D, Wie L, et al.: Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab 2013;15:853-862.
10. Locatelli F, Aljama P, Barany P, et al.: Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004;19:ii1-ii47.
11. KDOQI; National Kidney Foundation: KDOQI clinical practice guidelines and clinical recommendations for anemia in chronic kidney disease. Am J Kidney Dis 2006;47: S9-S145.
12. Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
13. Matsuo S, Imai E, Horio M, et al.: Collaborators developing the Japanese equation for estimated GFR: revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009;53:982-992.
14. Ferrannini E, Baldi S, Frascerra S, et al.: Renal handling of ketones in response to sodium-glucose cotransporter 2 inhibition in patients with type 2 diabetes. Diabetes Care 2017;40:771-776.
15. Layton AT, Vallon V, Edwards A: Predicted consequences of diabetes and SGLT inhibition on transport and oxygen consumption along a rat nephron. Am J Physiol Renal Physiol 2016;310:F1269-F1283.
16. Chang YK, Choi H, Jeong JY, et al.: Dapagliflozin, SGLT2 inhibitor, attenuates renal ischemia-reperfusion injury. PLoS One 2016;11:e0158810.
17. Rosenberger C, Mandriota S, Jürgensen JS, et al.: Expression of hypoxia-inducible factor-1alpha and -2alpha in hypoxic and ischemic rat kidneys. J Am Soc Nephrol 2002; 13:1721-1732.
18. Vallon V, Rose M, Gerasimova M, et al.: Knockout of Naglucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitus. Am J Physiol Renal Physiol 2013;304: F156-F167.
19. Ash SR, Cuppage FE: Shift toward anaerobic glycolysis in the regenerating rat kidney. Am J Pathol 1970;60:385-402.
20. Lan R, Geng H, Singha PK, et al.: Mitochondrial pathology and glycolytic shift during proximal tubule atrophy after ischemic AKI. J Am Soc Nephrol 2016;27: 3356-3367.
21. Farsijani NM, Liu Q, Kobayashi H, et al. Renal epithelium regulates erythropoiesis via HIF-dependent suppression of erythropoietin. J Clin Invest 2016;126:1425-1437.
22. Koury ST, Bondurant MC, Koury MJ: Localization of erythropoietin synthesizing cells in murine kidneys by in situ hybridization. Blood 1988;71:524-527.
23. Obara N, Suzuki N, Kim K, et al.: Repression via the GATA box is essential for tissue-specific erythropoietin gene expression. Blood 2008;111:5223-5232.
24. Bailey CJ, Gross JL, Pieters A, et al.: Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, doubleblind, placebo-controlled trial. Lancet 2010;375:2223-2233.
25. Osonoi T, Gouda M, Kubo M, et al.: Effect of canagliflozin on urinary albumin excretion in Japanese patients with type 2 diabetes mellitus and microalbuminuria: a pilot study. Diabetes Technol Ther 2018;20:681-688.
26. Sano M, Takei M, Shiraishi Y, et al.: Increased hematocrit during sodium-glucose cotransporter 2 inhibitor therapy indicates recovery of tubulointerstitial function in diabetic kidneys. J Clin Med Res 2016;8:844-847.
27. Zeisberg M, Kalluri R: Physiology of the renal interstitium. Clin J Am Soc Nephrol 2015;10:1831-1840.
28. O'Neill J, Fasching A, Pihl L, et al.: Acute SGLT inhibition normalizes O2 tension in the renal cortex but causes hypoxia in the renal medulla in anaesthetized control and diabetic rats. Am J Physiol Renal Physiol 2015;309:F227-F234.
29. Ferrannini E, Mark M, Mayoux E: CV protection in the EMPA-REG OUTCOME trial: a "thrifty substrate" hypothesis. Diabetes Care 2016;39:1108-1114.
30. Nangaku M: Chronic hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure. J Am Soc Nephrol 2006;17:17-25.
31. Terami N, Ogawa D, Tachibana H, et al.: Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice. PLoS One 2014;9: e100777.
32. Thomas MC, Burns WC, Cooper ME: Tubular changes in early diabetic nephropathy. Adv Chronic Kid Dis 2005;12: 177-186.
33. Takashima H, Yoshida Y, Nagura C, et al.: Renoprotective effects of canagliflozin, a sodium glucose cotransporter 2 inhibitor, in type 2 diabetes patients with chronic kidney disease: a randomized open-label prospective trial. Diab Vasc Dis Res 2018;15:469-472.